IMpower 110 is a phase III randomized study comparing atezolizumab (anti-PD-L1) monotherapy versus chemotherapy in chemotherapy-naïve patients with non-squamous or squamous stage IV NSCLC selected on the basis of PD-L1 expression. Here, CD274 is linked to non-small cell lung carcinoma.